Close Menu

NEW YORK (GenomeWeb) – Roche today said that its Cobas HIV-1 and HCV next-generation viral load monitoring assays have received CE marking.

The Cobas HIV-1 assay simultaneously amplifies and detects two separate regions of the HIV-1 genome to quantify the amount of viral RNA in the patient's blood. The Cobas HCV assay employs the firm's dual-probe approach to detect hepatitis C RNA. Both assays are available for use on the Cobas 6800 and 8800 systems.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.